asengeprast
Phase 2- Indications
- Systemic sclerosis
Company intelligence / Profile preview
Stoic Venture Capital is an Australian venture fund investing in emerging science and frontier technologies at the seed and pre-seed stage. Their life science/biotech investments include therapeutics for systemic sclerosis (Certa Therapeutics – FT011 in Phase 2 with positive results), respiratory viral infection prevention (ENA Respiratory – lead candidate in Phase 2 showing reduced duration of influenza A infection), precision oncology surgery/imaging/therapy (Ferronova), novel therapies for psychiatric disorders/substance use disorder (Kinoxis Therapeutics). They have supported at least four exits and have a track record of successful fundraising rounds for their portfolio companies.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Stoic Venture Capital.